VIA
NRIX icon

Virtus Investment Advisers’s Nurix Therapeutics NRIX Stock Holding History

Virtus Investment Advisers’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$468K Buy
19,304
+5,005
+35% +$85.3K 0.11% 218
2026
Q1 		$222K Buy
14,299
+350
+3% +$5.8K 0.06% 328
2025
Q4 		$265K Buy
13,949
+4,435
+47% +$63.7K 0.07% 304
2025
Q3 		$87.9K Buy
9,514
+1,652
+21% +$17.2K 0.03% 430
2025
Q2 		$89.5K Sell
7,862
-124
-2% -$1.34K 0.03% 380
2025
Q1 		$94.9K Buy
+7,986
New +$134K 0.03% 429

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Virtus Investment Advisers's NRIX Position: Q2 2026 in Review

Virtus Investment Advisers increased its Nurix Therapeutics (NRIX) stake by 35% in Q2 2026, buying an estimated $85.3K and bringing the position to 19,304 shares worth $468K. The position accounts for 0.11% of the portfolio, ranked #218.

Virtus Investment Advisers first reported a position in NRIX in Q1 2025 and has held it in 6 quarters since. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Virtus Investment Advisers held 19,304 shares of Nurix Therapeutics worth $468K as of Q2 2026.
  • Virtus Investment Advisers bought 5,005 Nurix Therapeutics shares in Q2 2026, an estimated $85.3K.
  • Nurix Therapeutics made up 0.11% of Virtus Investment Advisers's portfolio in Q2 2026, its #218 holding.
  • Virtus Investment Advisers first reported a position in Nurix Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.